Investor Presentaiton
Financial Ratios
Growth (%)
SUN
PHARMA
FY11
FY12
FY13
FY14
FY15
Net Sales
Gross Profit
EBITDA
42.8
39.9
40.4
42.4
70.5
46.3
49.5
43.9
44.4
55.4
43.2
66.5
50.9
45.0
9.9
Net Profit
34.4
46.3
12.3
5.3
44.5
Net Profit (Adjusted)
34.4
46.3
34.3#
58.7#
(15.6)#
Margins (%)
Gross Margin
74.4
79.5
81.5
82.6
75.3
EBITDA Margin (%)
34.1
40.6
43.7
44.5
28.6
Net Margin
31.7
33.2
26.5
19.6
16.6
Net Margin (Adjusted)
31.7
33.2
31.7#
35.4#
17.5#
Return (%)
ROCE
20.3
23.8
26.7
26.9
17.8
ROE
Others
Debt/Equity
Fully Diluted EPS (Rs) Post bonus
Fully Diluted EPS (Rs) Post bonus (Adjusted)
R&D Spend % of Net Sales
Revenue
Capital
21.0
23.8
25.7
30.9
20.4
0.04
0.02
0.01
0.13
0.30
8.8
12.8
14.4
15.2
18.9
8.8
12.8
17.2#
27.3 #
19.9 #
5.8
5.6
6.3
6.5
7.2
5.4
5.1
5.9
6.2
6.7
0.4
0.5
0.4
0.3
0.4
© Sun Pharmaceutical Industries Limited. All Rights Reserved.
# Adjusted for Rs 5.83 bn provision related to generic Protonix settlement for the year 2012-13.
Adjusted for Rs 25.17 bn provision related to generic Protonix settlement for the year 2013-14.
Adjusted for Rs 2.4 bn for settlement provision for Texas Medicaid Program litigation for 2014-15.
49View entire presentation